RIPK2 is a therapeutic target for autoimmune and inflammatory diseases such as inflammatory bowel disease (IBD) and Crohn’s disease [84,85] and is an emerging therapeutic target in metastatic castration-resistant prostate cancer [86]. Here, RIPK2 is linked to Crohn disease.